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Abstract
Background: There are concerns that testing for type 2 diabetes is low and many people with
diabetes are not diagnosed. We sought to describe the rates of diabetes-related lab testing in
Ontario from 1995–2005, among adults without diabetes, and to explore the extent to which the
Canadian clinical practice guidelines for screening are being followed.
Methods: Descriptive counts of outpatient diabetes laboratory tests performed within Ontario's
publicly funded, provincial health insurance program were recorded. The study population was
Ontario residents, 20 years and older from 1995 to 2005 (9.3 million people in 2005). The Ontario
Diabetes Database, a cumulative registry derived from administrative health records, was used to
exclude people who had physician-diagnosed diabetes (n = 839,127 in 2005) from the primary
analyses. Diabetes tests included serum blood glucose (SBG), hemoglobin A1c (HbA1c), and oral
glucose tolerance tests (OGTT).
Results: In 2005, 37% of Ontario adults without pre-existing diabetes were tested with an SBG
test, a 28% increase from 1995. The age-adjusted proportion of adults without diabetes undergoing
a HbA1c test increased from 1.7% in 1995 to 6.0% in 2005. In 2005, a similar number of HbA1c
tests were performed for individuals with diabetes (483,746) and without diabetes (496,616)
despite large differences in the two groups' denominators. Less than 1% of Ontarians underwent
OGTT testing in any year between 1995–2005. Nearly two-thirds of adults age 40 years and over
had an SBG test over a 3-year period (April 1, 2002–March 31, 2005), in accordance with the
Canadian Diabetes Association recommendations.
Conclusion: Diabetes testing is common and has increased over the last ten years. Despite its
absence in Canada's diabetes screening recommendations, HbA1c testing among individuals
without diabetes is increasing rapidly, and OGTT, which is recommended, is rarely performed.
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Background
Diabetes and its complications are a significant cause of
morbidity and mortality, and there is evidence to suggest
an increasing burden of this disease both in Canada and
globally [1,2]. Recent estimates from the province of
Ontario suggest that 8.8% of Ontario adults have physi-
cian-diagnosed diabetes, which is up 69% from 1995 [3].
This increase has been attributed to a rise in type 2 diabe-
tes (diabetes) cases, driven by an increase in obesity rates
[4-8]. However, greater screening for diabetes over the last
decade may have also contributed to these findings. Ear-
lier studies have suggested that up to one-third of all 'true'
diabetes cases are undiagnosed [9-12]. With increasing
diabetes awareness and the recent publication of screen-
ing guidelines, the proportion of undiagnosed diabetes
may have declined.
Because type 2 diabetes can remain asymptomatic for up
to 10 years [13], in Canada two clinical guidelines recom-
mend screening for the detection of diabetes in adults.
Since 1998, the Canadian Diabetes Association (CDA)
has recommended screening individuals aged 45 years
and older every three years with a fasting blood glucose
(FPG) test, and earlier and/or more frequently for individ-
uals with risk factors [14]. In 2003, the CDA reduced the
age to begin screening to age 40 and added a new recom-
mendation for oral glucose tolerance testing (OGTT) for
individuals with a FPG result of 5.7 to 6.9 mmol/L and at
least one risk factor for diabetes [15]. However these rec-
ommendations were predominantly consensus-driven,
due to insufficient evidence of direct benefits from screen-
ing (Grade D) [14,15]. The original CDA guidelines, pub-
lished in 1992, did not include any screening
recommendations outside of pregnancy [16]. The Cana-
dian Task Force on Preventive Health Care [17] recom-
mends screening only for adults with established
hypertension or hyperlipidemia, for whom benefits of
early diabetes detection and treatment have been shown.
We sought to explore trends in diabetes-related lab testing
in Ontario from 1995 to 2005 in a descriptive analysis.
Our first objective was to determine whether diabetes test-
ing among Ontario adults without diabetes has increased
over the last decade. Our second objective was to explore
the extent to which the CDA screening guidelines are
being followed in the province of Ontario, by examining
how many Ontarians received blood glucose laboratory
testing in accordance to the CDA guidelines. We chose to
focus on the CDA guidelines because they affect a large
population and they are increasingly referenced as a
screening and testing strategy.
Methods
Data sources
Data were extracted from anonymised administrative
health databases that include records for all individuals
eligible for health services under the Ontario Health
Insurance Plan (OHIP). All Ontario residents are eligible
for OHIP coverage after 3 months of residency in the prov-
ince. Legislation prohibits the private delivery of services
covered under OHIP, including laboratory testing. The
OHIP database was used to identify laboratory service
claims for diabetes testing. We obtained demographic
information from the Ontario Registered Persons Data-
base (RPDB), and diabetes status from the Ontario Diabe-
tes Database (ODD) [18]. These databases were linked
anonymously using unique encrypted health card num-
bers.
Data from April 1, 1995 to March 31, 2006 were extracted
for analysis. All data extraction and analyses were carried
out using SAS (Version 9.1).
Base population
A distinct base population was defined for each fiscal year
under study (1995 to 2005), which was comprised of all
Ontario adults aged 20 years or older recorded in the
RPDB.
Exclusion criteria
Persons with previously diagnosed diabetes (prevalent
diabetes) were removed from each fiscal-year cohort.
These individuals were identified using the ODD, a cumu-
lative diabetes registry that uses administrative health
records to determine diabetes status. Any individual hav-
ing at least one hospital admission or two physician
claims bearing a diabetes diagnosis within two years is
defined as having physician-diagnosed diabetes and is
included in the database. Women with gestational diabe-
tes are excluded from the registry. The ODD has been val-
idated using primary health care data, and shown to have
a sensitivity of 86% and a specificity of 97%. A detailed
description of its methodology can be found elsewhere
[18]. Incident cases of diabetes were not excluded.
Determination of diabetes-related laboratory tests
Ontario adults without diabetes who underwent diabetes-
related laboratory tests were identified using OHIP claims
bearing their encrypted health card numbers. The OHIP
database records all laboratory tests performed outside of
hospitals. The diabetes-related tests of interest were serum
blood glucose (SBG) (codes G002, L111, L112), hemo-
globin A1c (HbA1c) (code L093), and oral glucose toler-
ance test (OGTT) (code L104) (17). If an individual had
more than one SBG record (code L111) in the same day,
this was considered to represent one OGTT rather than
two SBG tests. Glucose tolerance tests in pregnancy haveBMC Health Services Research 2009, 9:41 http://www.biomedcentral.com/1472-6963/9/41
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their own unique fee code and were excluded from our
analyses. The SBG code does not discriminate between
fasting and random serum blood glucose measurements.
Records for the laboratory fee code of L700, a patient doc-
umentation and specimen collection fee submitted for the
processing of any lab test in Ontario, were also collected
as a measure of general laboratory testing. Only one L700
claim can be submitted per patient per day, regardless of
how many tests are carried out for an individual [19].
OHIP records for HbA1c and OGTT testing in 2005 were
also reviewed for individuals with diagnosed diabetes.
Percentage of Ontarians tested per fiscal year
For each laboratory test, the percentage of Ontarians aged
20 and older tested was determined for each fiscal year
from 1995 to 2005. The numerator was the number of
individuals who underwent at least one test of interest
that year. For each test, individuals contributed equally
whether they had one or multiple tests within each year.
The denominator for each year was the number of
Ontario adults aged 20 years or older (based on Statistics
Canada Census population counts), minus the number of
prevalent diabetes cases derived from the ODD. Estimates
of the Ontario population provided by Statistics Canada
were used for years in between Census sampling. To adjust
for differences in the age structure of the Ontario popula-
tion over time, direct age standardization using the 1991
Canadian Census population was performed.
Sensitivity analysis
For people newly diagnosed with diabetes, our dataset
provided only the year in which diabetes was diagnosed.
Thus, for lab tests performed during the year a person was
newly diagnosed with diabetes, we could not determine
whether their lab tests were ordered before (for screening
and diagnosis) or after the establishment of a diabetes
diagnosis. To investigate the extent to which this may have
influenced our results, a sensitivity analysis was per-
formed in which we excluded all lab tests carried out in
individuals diagnosed with diabetes in the same year
(incident cases).
Percentage of Ontarians over age 40 tested over one to 
five years
To estimate the number of Ontarians who were screened
in accordance with the CDA guidelines, we first identified
a cohort of Ontarians who were free of diabetes on April
1st 2005. Next, we examined the percentage of people
tested in the most recent year (April 1, 2004 to March 31,
2005). Next, the percentage of people who were tested
over 2, 3, 4 and 5 year periods was estimated by the corre-
sponding historic data (e.g. the 5 year period was April 1,
2000 to March 31, 2005). Only Ontarians age 40 years or
older for the entire 5-year period were included in these
estimates.
Research ethics
Ethics approval was obtained from the institutional
review board at Sunnybrook Health Sciences Complex,
Toronto, Ontario, Canada.
Results
Both diabetes-related and general laboratory tests are
commonly performed (Figure 1 and Table 1). SBG and
HbA1c testing have increased steadily since 1995, despite
a relative plateau in the rate of laboratory testing in gen-
eral (approximately 50% of Ontarians received at least
one lab test yearly). In 2005, the age-adjusted percentage
of Ontario adults without diabetes undergoing an SBG
test was 37%, representing a 28% increase since 1995.
The most striking increase in diabetes-related testing was
observed for HbA1c tests, which increased approximately
10% per year or 250% from 1995 to 2005 (Figure 1). The
age-adjusted proportion of adults without diabetes who
underwent the test in 2005 was 6.0%, compared to 1.7%
in 1995. In 2005, 8.4% of adults aged 40 years and older,
without diabetes underwent a HbA1c test (results not
shown). In 2005, HbA1c was performed for 496,616 indi-
viduals without diabetes, and for 483,746 individuals
with diagnosed diabetes. An additional 54,706 tests were
completed amongst individuals newly diagnosed with
diabetes in 2005 bringing the total number of diabetes
patients tested to 538,452 (64% of diabetics). The OGTT
continues to be underused with less than 1% of adults
being tested, and its use has decreased 60% from 0.08%
in 1995 to 0.03% in 2005 (Figure 1). In 2005, 3,241 indi-
viduals underwent at least one OGTT. Among the individ-
uals who underwent an OGTT in 2005, 2,452 did not
have diabetes, 504 had a pre-existing diagnosis of diabe-
tes, and 285 were newly diagnosed with diabetes in 2005.
The results of the sensitivity analysis demonstrate that
these broad trends in diabetes laboratory testing still hold,
even if all tests conducted among incident cases of diabe-
tes are removed from the analysis (Table 1).
Table 2 documents the percentage and number of people
age 40 or older who received a SBG test increased when
more than one year of historical data was examined. 40%
of people were tested within one year (2005), 63% by
three years (the screening interval recommended by
CDA), and by five years, 71% had undergone at least one
SBG test.
Discussion
This study documents a 28% increase in serum glucose
testing between 1995 and 2005 among Ontarians without
diabetes. People who advocate for screening may find the
current level of testing unacceptably low. Others may be
encouraged that the level of testing (two thirds of Ontari-
ans recommended to be screened by the CDA areBMC Health Services Research 2009, 9:41 http://www.biomedcentral.com/1472-6963/9/41
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Percentage of Ontario adults (20 and older) tested with diabetes-related investigations 1995–2005 (Age-standardized using  1991 Canadian Census population) Figure 1
Percentage of Ontario adults (20 and older) tested with diabetes-related investigations 1995–2005 (Age-stand-
ardized using 1991 Canadian Census population).
Table 1: Un-standardized number of diabetes-related lab tests among Ontario adults (20 and older) without an established diagnosis of 
diabetes in the preceding fiscal year 1995–2005.
Year Processing of any lab test Serum blood glucose HbA1c OGTT
2005 4,512,614 (70,020) 3,301,311 (67,299) 496,616 (54,706) 2,452 (285)
2004 4,404,670 (71,258) 3,180,760 (68,675) 464,471 (54,040) 2,188 (254)
2003 4,319,405 (64,986) 3,093,533 (62,661) 398,624 (47,536) 1,430 (151)
2002 4,294,975 (65,392) 3,040,925 (62,801) 350,966 (46,843) 1,357 (163)
2001 4,204,571 (62,655) 2,931,753 (59,851) 305,803 (43,154) 1,352 (210)
2000 4,142,494 (55,488) 2,819,595 (52,663) 261,396 (37,352) 1,338 (154)
1999 4,039,243 (53,371) 2,691,883 (50,784) 228,395 (35,678) 11,200 (492)
1998 4,037,268 (50,665) 2,621,334 (48,158) 207,735 (32,330) 5,803 (1,006)
1997 3,917,028 (49,002) 2,524,294 (46,734) 188,019 (30,488) 6,640 (1,327)
1996 3,731,845 (43,963) 2,274,260 (41,707) 144,266 (24,843) 25,082 (1,982)
1995 3,663,118 (43,100) 2,222,656 (41,321) 126,192 (22,747) 5,944 (1,303)
The number of tests conducted in newly diagnosed diabetes cases (incident cases in the year under study) is expressed in parentheses.BMC Health Services Research 2009, 9:41 http://www.biomedcentral.com/1472-6963/9/41
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screened) is similar to other well-established programs
such as mammography [20,21] and papanicolaou (Pap)
testing [22,23], despite the absence of a formal diabetes
screening program. Still others may find the level of test-
ing too high, given the more conservative recommenda-
tions of the Canadian Task Force on Preventive Health
Care and the grade D level of evidence of the CDA recom-
mendations.
OGTT testing in Ontario is very uncommon and has
declined over the last 10 years. Lyon et al. [24] showed
14.8% of residents in the Canadian city of Calgary tested
with a serum glucose fell into the range of 5.7 and 6.9
mmol/L and would have required an OGTT based on the
CDA guidelines. They noted that if these were all followed
by an OGTT, as recommended by the CDA, it would result
in an additional 2823 OGTTs per month, 19 times greater
that their baseline rate of 150 tests per month (excluding
tests in pregnant women). In Ontario, 0.03% of the total
population (3,241 individuals with and without diabetes)
received an OGTT in 2005. This number likely over-esti-
mates the true number of OGTT carried out in Ontario as
our study methodology counted any individual who
underwent two SBG tests in a single day as undergoing an
OGTT. These individuals may in fact represent individuals
presenting for fasting and postprandial blood glucose
measurements. However, this bias towards over-estima-
tion of OGTT further reinforces our finding that this test is
infrequently used in Ontario. The CDA recommendations
for OGTT are clearly unpopular with clinicians and/or
patients. For example, the ADDITION trial of population-
based screening for diabetes in the Netherlands found a
dropout rate of 23% among participants advised to
undergo an OGTT as part of the screening algorithm [25].
The infrequent use of the OGTT in Ontario is likely to
have important consequences with respect to diabetes
case detection. Using only fasting plasma glucose will fail
to diagnose approximately 30% of individuals with diabe-
tes [26,27], and an even greater proportion among the
elderly [28].
Conversely, our study found a 250% increase in HbA1c
testing among persons without diabetes, a test that has
not been recommended for diabetes screening due to con-
cerns regarding reliability [29]. If this rate of increase is
sustained, the number of individuals without diabetes
who undergo HbA1c testing each year may soon exceed
the number of patients with diabetes tested. These data
suggest that some clinicians may be using the HbA1c test
as an alternative to the recommended FPG and OGTT to
diagnose diabetes. Clinicians and patients may prefer the
HbA1c test, as there is no requirement for fasting or mul-
tiple blood draws, there is a threshold level associated
with retinopathy and cardiovascular mortality [29], and it
can be used to guide treatment decisions in the manage-
ment of diabetes. A recent systematic review [30] con-
cluded that the HbA1c and FPG are equally effective
screening tools for the detection of diabetes. The com-
bined use of HbA1c and FPG has been shown to have
greater sensitivity than the use of FPG alone [31] in diabe-
tes diagnosis but the impact of additional HbA1c testing
in Ontario on diabetes case detection is uncertain, partic-
ularly in light of the low uptake of the OGTT.
The strengths of our study include the use of population-
based, individually linked administrative data and the use
of a validated diabetes database to exclude diabetes
patients [18]. However, there are some important limita-
tions that merit emphasis. First, we were not able to differ-
entiate between fasting and random serum blood glucose
tests using our data. Since only fasting blood glucose test-
ing is recommended for diabetes screening, we could not
determine which tests were ordered specifically for the
purpose of asymptomatic diabetes screening versus case
finding in symptomatic persons. Second, diabetes cases
were excluded based on a registry that is associated with a
14% false negative rate, therefore some persons with dia-
betes may have been misclassified and included in our
study. Third, although we have captured all diabetes-
related laboratory services billed to OHIP, we were not
able to capture tests carried out within hospital in-
Table 2: Serum blood glucose testing in a cohort of Ontario adults aged 40 years and older, without diabetes, 2001–2005.
Time period Number new 
tests
Denominator* % newly tested Cumulative no. 
tested
Denominator 
(total)
Cumulative % 
tested
Never tested
1 year (2005) 2,043,156 5,071,304 40.30% 2,043,156 5,071,304 40.30%
2 years 
(2004–2005)
766,250 3,028,148 25.30% 2,809,406 5,071,304 55.40%
3 years 
(2003–2005)
374,702 2,261,898 16.60% 3,184,108 5,071,304 62.80%
4 years 
(2002–2005)
244,953 1,887,196 13.00% 3,429,061 5,071,304 67.60%
5 years 
(2001–2005)
185,139 1,642,243 11.30% 3,614,200 5,071,304 71.30% 28.70%
* Denominator refers to the number of individuals in the cohort who had not previously undergone a serum blood glucose test during the study 
period (2001–2005)BMC Health Services Research 2009, 9:41 http://www.biomedcentral.com/1472-6963/9/41
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patients. However this limitation at most resulted in an
underestimate of our findings.
Conclusion
In summary, diabetes-related lab testing is common in
Ontario and has increased substantially from 1995 to
2005. HbA1c testing for people without diabetes is com-
monly performed, but not recommended – while OGTT is
recommended but rarely performed. Regardless, the
majority of Ontarians are likely being tested for diabetes,
despite the controversy regarding diabetes screening and
the lack of a formal screening program. The rise in testing
for diabetes possibly, if not likely, contributed to the over-
all increase in diabetes observed during this time period
[3]. Whether the increased testing resulted in a change in
the ratio between diagnosed and undiagnosed cases of
diabetes is uncertain but should be addressed in future
studies which explore the socio-demographic characteris-
tics and co-morbidities of those who undergo diabetes
testing.
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